|
Research Interests:
Dr. Dacic is a thoracic surgical pathologist and Director of FISH and Developmental Laboratory at the University of Pittsburgh Medical Center. Her diagnostic expertise includes neoplastic and non-neoplastic diseases of the lung, and mediastinum and lung transplantation. FISH and Developmental Laboratory offers a large spectrum of FISH and ISH diagnostic and prognostic tests developed under her direct supervision and guideline. Her primary research interests relate to molecular profiling of lung carcinoma and mesotheliomas and detection of biomarkers that have potential to be used clinically for diagnosis, prognostication and treatment of lung carcinoma and mesotheliomas. These interests resulted in numerous invited lectureships and courses in national and international societies and forums. She is an observing member of the pathology committee for the International Association for Study of Lung Cancer (IASLC) and a member of International Mesothelioma Panel. Dr. Dacic serves as a Deputy Chief Editor of the Archives of Pathology and Laboratory Medicine, and is the editorial boards for American Journal of Clinical Pathology and Advances in Anatomic Pathology. Dr. Dacic is a recipient of Arthur Purdy Stout Prize in 2011 for her research contributions that have had a major impact on diagnostic pathology.
Selected Publications:
View Dr. Dacic's publications on PubMed
Dacic S, Sasatomi E, Swalsky PA, Finkelstein SD, Yousem SA. Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping . Am J Surg Pathol 2002; 26(4):510-6
Dacic S, Ionescu DN, Finkelstein SD, Yousem SA. Patterns of allelic loss of multiple synchronous adenocarcinomas of the lung. Am J Surg Pathol 2005; 29(7):897-904.
Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, Dacic S. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007; 65(5):2345-50.
Gradowski JF, Mantha GS, Hunt JL, Dacic S. Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs. Diagn Mol Pathol 2007; 16(2):87-90.
Chiosea S, Cagle P, Krasinskas A, Zander D, Mitchell K, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008; 21 (6):742-7.
Dacic S, Kothmaier H, Land S, Shuai Y , Halbwedl I, Morbini P, Murer B, Comin CE, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle PT, HH. Prognostic significance of p16/CDKN2a deletion in pleural malignant mesotheliomas. Virchows Arch 2008;453(6):627-35.
Monaco S, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S. A comparison of EGFR and KRAS status in primary and matched metastatic pulmonary adenocarcinoma. Hum Pathol 2010;41(1):94-102.
Dacic S, Shuai Y, Yousem SA, Ohori NP, Nikiforova MN. Clinico-pathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010;23(2):159-68;
Rodig SJ, Mino-Kenudson M, Dacic S, Yeap B Y,. Barletta JA, Stubb H, Law K, Lindeman N, Mark E, Shaw A, Pasi J, Lynch T, Johnson BE, Iafrate AJ, and Chirieac LR. Unique Clinicopathologic features characterize ALK rearranged lung adenocarcinoma in the Western population. Clin Cancer Res 2009; 15(16):5216-23.
Chiosea S, Shuai Y, Cieply K, Nikiforova MN, Dacic S. EGFR FISH positive lung adenocarcinoma: incidence of co-existing KRAS and BRAF mutations. Hum Pathol
2010 ; 41(8):1053-60.
Dacic S, Kelly L, Shuai Y, Nikiforova MN. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010; 23(12):1577-82.
Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, Laucirica R, Ro JY, Kerr KM. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011;135(1):110-6
Monaco SE, Krasinskas AM, Kamat, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemistry in mesothelial proliferations diagnosed by surgical pathology and cytology. Am J Clin Pathol 2011;135(4):619-27
Chiosea S, Sherer C, Jelic T, Dacic S. KRAS Mutant allele specific imbalance in lung adenocarcinoma. Mod Pathol 2011 Jul 8. doi: 10.1038/modpathol.2011.109. [Epub ahead of print]
|
